NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ELOX Stock Alerts $0.82 +0.02 (+2.48%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.79▼$0.8350-Day Range$0.75▼$1.1052-Week Range$0.40▼$10.90Volume6,670 shsAverage Volume9,663 shsMarket Capitalization$2.59 millionP/E RatioN/ADividend YieldN/APrice Target$55.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Eloxx Pharmaceuticals alerts: Email Address Eloxx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside6,566.7% Upside$55.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.91) to ($7.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoverageEloxx Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ELOX. Previous Next 0.0 Dividend Strength Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELOX. Previous Next 2.5 News and Social Media Coverage News SentimentEloxx Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for ELOX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders20.20% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.90% of the stock of Eloxx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($7.91) to ($7.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Read More ELOX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELOX Stock News HeadlinesApril 17, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finance.yahoo.comAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 16, 2024 | globenewswire.comEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesApril 5, 2024 | msn.comGene therapy and glycoside drugs offer new hope for polycystic kidney disease treatmentMarch 26, 2024 | markets.businessinsider.comNasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech ProspectsMarch 13, 2024 | finanznachrichten.deAlmirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesMarch 13, 2024 | globenewswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 13, 2024 | businesswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesFebruary 22, 2024 | benzinga.comEloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest ReportFebruary 16, 2024 | barrons.comVertex Pharmaceuticals Inc.February 6, 2024 | finance.yahoo.comEloxx Pharmaceuticals, Inc. (ELOX)January 30, 2024 | msn.comCNS Pharmaceuticals prices $4M public offeringDecember 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)December 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)December 13, 2023 | finance.yahoo.comOff the Beaten Path: 3 Delisted Stocks for The Speculative InvestorDecember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO), Crispr Therapeutics AG (CRSP) and Biomea Fusion (BMEA)November 22, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)November 14, 2023 | msn.comHoth stock jumps on positive FDA feedback on drug HT-KITNovember 13, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNovember 8, 2023 | morningstar.comEloxx Pharmaceuticals Inc ELOXOctober 9, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaSeptember 21, 2023 | seekingalpha.comEloxx Pharmaceuticals prices $2M stock offeringSeptember 19, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Announces Registered Direct Offering - Quick FactsSeptember 19, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSeptember 18, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeSee More Headlines Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELOX CUSIPN/A CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees18Year Founded2013Price Target and Rating Average Stock Price Target$55.00 High Stock Price Target$55.00 Low Stock Price Target$55.00 Potential Upside/Downside+6,566.7%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($9.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,060,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-203.00% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.92) per share Price / Book-0.17Miscellaneous Outstanding Shares3,140,000Free Float2,508,000Market Cap$2.59 million OptionableNot Optionable Beta2.75 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Sumit Aggarwal M.B.A. (Age 51)President, CEO & Director Comp: $839.67kMr. Daniel E. Geffken M.B.A. (Age 67)Interim CFO, Principal Financial Officer & Principal Accounting Officer Comp: $63.96kMs. Barbara RyanInvestor Relations OfficerDr. Ali Hariri M.D.Chief Medical OfficerKey CompetitorsGamida CellNASDAQ:GMDAAvalon GloboCareNASDAQ:ALBTGamida CellNASDAQ:GMDAQKiromic BioPharmaNASDAQ:KRBPTC BiopharmNASDAQ:TCBPView All Competitors ELOX Stock Analysis - Frequently Asked Questions What is Eloxx Pharmaceuticals' stock price target for 2024? 0 brokerages have issued 12 month price targets for Eloxx Pharmaceuticals' shares. Their ELOX share price targets range from $55.00 to $55.00. On average, they predict the company's share price to reach $55.00 in the next year. This suggests a possible upside of 6,566.7% from the stock's current price. View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts. How have ELOX shares performed in 2024? Eloxx Pharmaceuticals' stock was trading at $1.20 at the start of the year. Since then, ELOX shares have decreased by 31.3% and is now trading at $0.8250. View the best growth stocks for 2024 here. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share for the quarter, topping the consensus estimate of ($2.97) by $0.05. What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO? 1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELOX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
